WolverHeme Happy Hour Bernard Marini, Anthony Perissinotti, et al.

In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!



Abstracts discussed:


https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL
https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic
https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab
https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab)
https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)

OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!



Abstracts Discussed!


SYMPATICO (Ibrutinib + Ven in R/R MCL):
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Nivo-AVD in elderly Hodgkin Lymphoma:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL:
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
CAR-T in CNS Lymphoma:
https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data),
https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study)
Synthetic Control Arms:
https://ash.confex.com/ash/2023/webprogram/Paper177708.html
POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!):
https://x.com/Eddie_Cliff/status/1733901400822993257?s=20

In this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial!

Abstracts:


FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html
Revumenib Late Breaking Abstract:
https://ash.confex.com/ash/2023/webprogram/Paper192042.html
JNJ617 Menin Inhibitor Data:
https://ash.confex.com/ash/2023/webprogram/Paper172422.html
SAVE Trial (Revumenib + PO Dec/ven):
https://ash.confex.com/ash/2023/webprogram/Paper182337.html
Dec/Ven vs. 3+7 Randomized Phase II:
https://ash.confex.com/ash/2023/webprogram/Paper181347.html
NCRI AML18 RCT:
https://ash.confex.com/ash/2023/webprogram/Paper185956.html
Impact of NPM1+/FLT3+/MRD in AML17 and AML19:
https://ash.confex.com/ash/2023/webprogram/Paper179033.html
CBF and NPM1 MRD:
https://ash.confex.com/ash/2023/webprogram/Paper184848.html
Persistent MRD by PCR but Flow Negativity in CBF AML (Mast Cell Madness):
https://ash.confex.com/ash/2023/webprogram/Paper180275.html
MORPHO More MRD Analysis:
https://ash.confex.com/ash/2023/webprogram/Paper177929.html

In this episode, Anthony and Bernie are joined by two very special guests - Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin - to discuss the most interesting myeloma abstracts at the upcoming 2023 ASH meeting! Will any of these change practice? Listen to find out!



Abstracts Discussed:


https://ash.confex.com/ash/2023/webprogram/Paper188547.html
https://ash.confex.com/ash/2023/webprogram/Paper181765.html
https://ash.confex.com/ash/2023/webprogram/Paper177954.html
https://ash.confex.com/ash/2023/webprogram/Paper191911.html
https://ash.confex.com/ash/2023/webprogram/Paper179866.html
https://ash.confex.com/ash/2023/webprogram/Paper177546.html
https://ash.confex.com/ash/2023/webprogram/Paper178835.html
Also check out Manni's excellent tweetorial on some of these key abstracts:
https://x.com/ManniMD1/status/1726980328559133028?s=20

In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice!




Sorafenib observational study: https://pubmed.ncbi.nlm.nih.gov/30809038/
SORMAIN (sorafenib): https://pubmed.ncbi.nlm.nih.gov/32673171/
Chinese Sorafenib Phase III: https://pubmed.ncbi.nlm.nih.gov/32791048/
RADIUS (midostaurin): https://pubmed.ncbi.nlm.nih.gov/33288862/
AMLSG 16-10 (midostaurin): https://pubmed.ncbi.nlm.nih.gov/30563875/
MORPHO (EHA abstract): https://library.ehaweb.org/eha/2023/eha2023-congress/391322/faculty.presenters.bmt-ctn.1506.28morpho29.a.randomized.trial.of.the.flt3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmorpho